A novel therapeutic anti-ErbB3, ISU104 exhibits potent antitumorigenic activity by inhibiting ligand binding and ErbB3 heterodimerization

Mirim Hong, Youngki Yoo, Miyoung Kim, Ju Yeon Kim, Jeong Seok Cha, Myung Kyung Choi, Uijin Kim, Kyungyong Kim, Youngsoo Sohn, Donggoo Bae, Hyun Soo Cho, Seung Beom Hong

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

ErbB3, a member of the ErbB receptor family, is a potent mediator in the development and progression of cancer, and its activation plays pivotal roles in acquired resistance against anti-EGFR therapies and other standard-of-care therapies. Upon ligand (NRG1) binding, ErbB3 forms heterodimers with other ErbB proteins (i.e., EGFR and ErbB2), which allows activation of downstream PI3K/Akt signaling. In this study, we developed a fully human anti-ErbB3 antibody, named ISU104, as an anticancer agent. ISU104 binds potently and specifically to the domain 3 of ErbB3. The complex structure of ErbB3-domain 3::ISU104-Fab revealed that ISU104 binds to the NRG1 binding region of domain 3. The elucidated structure suggested that the binding of ISU104 to ErbB3 would hinder not only ligand binding but also the structural changes required for heterodimerization. Biochemical studies confirmed these predictions. ISU104 inhibited ligand binding, ligand-dependent heterodimerization and phosphorylation, and induced the internalization of ErbB3. As a result, downstream Akt phosphorylation and cell proliferation were inhibited. The anticancer efficacy of ISU104 was demonstrated in xenograft models of various cancers. In summary, a highly potent ErbB3 targeting antibody, ISU104, is suitable for clinical development.

Original languageEnglish
Pages (from-to)1142-1152
Number of pages11
JournalMolecular Cancer Therapeutics
Volume20
Issue number6
DOIs
Publication statusPublished - 2021 Jun

Bibliographical note

Funding Information:
H.-S. Cho was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (NRF-2016R1A5A1010764, NRF-2017M3A9F6029755, and NRF-2019M3E5D6063903), the Strategic Initiative for Microbiomes in Agriculture and Food grant funded by the Ministry of Agriculture, Food and Rural Affairs (918012-4), and a grant funded by ISU ABXIS Co. Ltd. M. Hong, M. Kim, K. Kim, Y. Sohn, and D. Bae were supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (HI16C0528). We thank the staff scientists for assistance with the Beamline 11C at the Pohang Light Source, Pohang Accelerator Laboratory.

Publisher Copyright:
© 2021 American Association for Cancer Research.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A novel therapeutic anti-ErbB3, ISU104 exhibits potent antitumorigenic activity by inhibiting ligand binding and ErbB3 heterodimerization'. Together they form a unique fingerprint.

Cite this